BR112014017985A2 - - Google Patents
Info
- Publication number
- BR112014017985A2 BR112014017985A2 BR112014017985A BR112014017985A BR112014017985A2 BR 112014017985 A2 BR112014017985 A2 BR 112014017985A2 BR 112014017985 A BR112014017985 A BR 112014017985A BR 112014017985 A BR112014017985 A BR 112014017985A BR 112014017985 A2 BR112014017985 A2 BR 112014017985A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593047P | 2012-01-31 | 2012-01-31 | |
| PCT/US2013/023781 WO2013116293A1 (en) | 2012-01-31 | 2013-01-30 | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014017985A2 true BR112014017985A2 (enExample) | 2017-06-20 |
| BR112014017985A8 BR112014017985A8 (pt) | 2017-07-11 |
Family
ID=47679114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014017985A BR112014017985A8 (pt) | 2012-01-31 | 2013-01-30 | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140378422A1 (enExample) |
| EP (1) | EP2809312A1 (enExample) |
| JP (1) | JP2015505562A (enExample) |
| KR (1) | KR20140117457A (enExample) |
| CN (1) | CN104093402A (enExample) |
| AU (1) | AU2013215251A1 (enExample) |
| BR (1) | BR112014017985A8 (enExample) |
| CA (1) | CA2861377A1 (enExample) |
| IN (1) | IN2014DN05869A (enExample) |
| MX (1) | MX2014009303A (enExample) |
| RU (1) | RU2014135436A (enExample) |
| WO (1) | WO2013116293A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201607334YA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| CA2974937C (en) | 2015-03-25 | 2023-09-05 | National Cancer Center | Therapeutic agent for bile duct cancer |
| WO2017100715A1 (en) | 2015-12-09 | 2017-06-15 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulator compounds |
| KR102486722B1 (ko) | 2015-12-17 | 2023-01-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 유방암 치료제 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR102793563B1 (ko) | 2016-03-04 | 2025-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| CA3048057A1 (en) | 2017-01-06 | 2018-07-12 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| MX2020007375A (es) * | 2018-01-10 | 2020-11-09 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. |
| MY203305A (en) | 2018-03-19 | 2024-06-23 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| TWI841598B (zh) * | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| MA54311A (fr) * | 2018-11-26 | 2022-03-02 | Taiho Pharmaceutical Co Ltd | Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie |
| CA3185174A1 (en) * | 2020-07-31 | 2022-02-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| US20240139208A1 (en) * | 2021-03-03 | 2024-05-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition containing cdk4/6 inhibitor and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (enExample) | 1962-09-13 | |||
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| KR101224410B1 (ko) | 2003-11-07 | 2013-01-23 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 퀴놀리논 화합물을 합성하는 방법 |
| WO2006081445A2 (en) * | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics Inc. | Treatment of metastasized tumors |
| AU2006247803B2 (en) * | 2005-05-13 | 2011-12-22 | Novartis Ag | Methods for treating drug resistant cancer |
| EP1904480A2 (en) | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| RU2433826C2 (ru) | 2005-11-29 | 2011-11-20 | Новартис Аг | Композиции хинолинонов |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
-
2013
- 2013-01-30 WO PCT/US2013/023781 patent/WO2013116293A1/en not_active Ceased
- 2013-01-30 KR KR1020147021140A patent/KR20140117457A/ko not_active Ceased
- 2013-01-30 JP JP2014555661A patent/JP2015505562A/ja active Pending
- 2013-01-30 RU RU2014135436A patent/RU2014135436A/ru unknown
- 2013-01-30 CA CA2861377A patent/CA2861377A1/en not_active Abandoned
- 2013-01-30 IN IN5869DEN2014 patent/IN2014DN05869A/en unknown
- 2013-01-30 US US14/375,145 patent/US20140378422A1/en not_active Abandoned
- 2013-01-30 BR BR112014017985A patent/BR112014017985A8/pt not_active Application Discontinuation
- 2013-01-30 CN CN201380006947.7A patent/CN104093402A/zh active Pending
- 2013-01-30 MX MX2014009303A patent/MX2014009303A/es unknown
- 2013-01-30 AU AU2013215251A patent/AU2013215251A1/en not_active Abandoned
- 2013-01-30 EP EP13703295.9A patent/EP2809312A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014DN05869A (enExample) | 2015-05-22 |
| MX2014009303A (es) | 2014-10-14 |
| JP2015505562A (ja) | 2015-02-23 |
| WO2013116293A1 (en) | 2013-08-08 |
| US20140378422A1 (en) | 2014-12-25 |
| BR112014017985A8 (pt) | 2017-07-11 |
| CN104093402A (zh) | 2014-10-08 |
| KR20140117457A (ko) | 2014-10-07 |
| EP2809312A1 (en) | 2014-12-10 |
| AU2013215251A1 (en) | 2014-08-14 |
| RU2014135436A (ru) | 2016-03-27 |
| CA2861377A1 (en) | 2013-08-08 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |